PRINCETON, N.J.– Battelle Ventures, LP, has spun out regenerativemedicine start-up NellOne Therapeutics, Inc. (NellOne), from the U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL), with an initial $1.5-million seed
investment from the fund and its Tennessee affiliate, Innovation Valley Partners.The investment will be tranched based on key technical milestones. (more…)

Richmond, VA. USA / Rosh Ha’Ayin, Israel, June 2nd, 2008 – EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, announced today that it successfully completed its latest round of funding of US $4 million. The round was extended from $2 million, as was announced on January 2008, to $4 million and was led by Eli Gilboa from Gilboa&Licht, who is the company’s chairman. To date, the company has raised a total US$7.3 million. With this additional capital, the company will be positioned to execute on its plan to commercialize its products, for market launch in early 2009. The addressable market for DermaStream™ advanced wound care products is estimated by industry analysts to be US$6 billion. (more…)

Greenville, SC: Selah Technologies, an advanced materials
manufacturer, announced today that it has closed on a $1.5 million Series A private financing round. This funding will enable the company to make considerable strides in the commercialization of its two core platform nanomaterials technologies, Selah DotsTM and Selah TubesTM. (more…)

DURHAM, N.C. – Proventys, Inc., a personalized medicine knowledge service provider, announced today that it secured $5.65M in Series A1 financing. Life sciences-focused venture capital firm Burrill & Company led the investment in Proventys. Timothy Thompson, formerly managing director of business development (mergers and acquisitions) at Aetna, joined
the company as president and CEO. (more…)

Blacksburg, VA: Intrexon Corporation, a privately held life sciences company focused on biotherapeutic control systems, announced today it has closed a $25 million Series C-2 financing by New River Management V, LP, a private investment fund managed by Third Security, LLC. Previous rounds of investment have been provided by New River Management IV,LP, New River Management V and NewVa Capital Partners, LP, a regional investment partnership. Funds and other entities managed by Third Security have invested a total of $56.5 million in Intrexon to date. (more…)

Research Triangle Park, NC - CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $1,000,000 in a Series B private financing round. The Company was founded in 2006 by Robert and Claudia Black (two of the founders of Sicel Technologies) and Suzanne Babcock (former VP of Troxler Electronics) and is headquartered in the Park Research Center in RTP. (more…)

Research Triangle Park, N.C.-CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $1,000,000 in a Series B private financing round. (more…)

Philadelphia, PA—Quaker BioVentures announced today that it has
closed its second fund with $420 million in total commitments, bringing Quaker BioVentures’ total assets under management to $700 million. Following its successful first $280 million fund, which invested in 24 companies, Quaker will maintain its unique
investment focus on life science companies in the Mid-Atlantic region, an opportunityrich, yet still underserved market. (more…)

Durham, NC– Aldagen, Inc. today announced it has raised $18.4 million in a private round of financing. The financing was obtained from existing investors, including Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds. The company plans to use the proceeds raised in this financing to further advance the development of its four clinical-stage product candidates and for general corporate purposes. (more…)

Durham, NC—A therapy that holds promise for enlisting the immune system in the fight against cancer, HIV and infectious disease just got a shot in the arm. Argos Therapeutics has closed a $35.2 million tranched Series C round led by TVM Capital with participation from new investors Mizuho Capital, Morningside Group and Japan Asia Investment Co. (more…)